Legend Biotech (LEGN) Receivables (2019 - 2024)
Legend Biotech (LEGN) has disclosed Receivables for 6 consecutive years, with $7.1 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Receivables fell 92.99% year-over-year to $7.1 million, compared with a TTM value of $7.1 million through Dec 2024, down 92.99%, and an annual FY2024 reading of $7.1 million, down 92.99% over the prior year.
- Receivables was $7.1 million for Q4 2024 at Legend Biotech, down from $100.8 million in the prior quarter.
- Across five years, Receivables topped out at $100.8 million in Q4 2023 and bottomed at $430000.0 in Q4 2022.
- Average Receivables over 5 years is $46.9 million, with a median of $50.7 million recorded in 2021.
- The sharpest move saw Receivables plummeted 99.15% in 2022, then surged 23349.07% in 2023.
- Year by year, Receivables stood at $75.6 million in 2020, then crashed by 32.99% to $50.7 million in 2021, then tumbled by 99.15% to $430000.0 in 2022, then soared by 23349.07% to $100.8 million in 2023, then plummeted by 92.99% to $7.1 million in 2024.
- Business Quant data shows Receivables for LEGN at $7.1 million in Q4 2024, $100.8 million in Q4 2023, and $430000.0 in Q4 2022.